These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32047887)

  • 1. Do ground-glass opacity-dominant features have prognostic significance in node-negative adenocarcinomas with invasive components of similar sizes?
    Han SJ; Jeon JH; Jung W; Seong YW; Cho S; Kim K; Jheon S
    Eur J Cardiothorac Surg; 2020 Jun; 57(6):1189-1194. PubMed ID: 32047887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Nakamura S; Fukui T; Kawaguchi K; Fukumoto K; Hirakawa A; Yokoi K
    Lung Cancer; 2015 Jul; 89(1):38-42. PubMed ID: 25963638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
    Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
    J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?
    Deng C; Jiang C; Ma X; Fu F; Wang S; Li Y; Zhang Y; Chen H
    Transl Lung Cancer Res; 2024 Jul; 13(7):1609-1619. PubMed ID: 39118885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?
    Lin B; Wang R; Chen L; Gu Z; Ji C; Fang W
    Transl Lung Cancer Res; 2021 Jun; 10(6):2487-2499. PubMed ID: 34295656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsolid Lesions Exceeding 3 Centimeters: The Ground-Glass Opacity Component Still Matters.
    Fan F; Zhang Y; Fu F; Gao Z; Zhao Y; Han H; Lai J; Wen Z; Ma X; Deng C; Ma Z; Wang S; Deng L; Li Y; Ye T; Chen H
    Ann Thorac Surg; 2022 Mar; 113(3):984-992. PubMed ID: 33839135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Chest; 2014 Jan; 145(1):66-71. PubMed ID: 24551879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of lymphovascular invasion for stage I lung adenocarcinoma based on the presence of ground-glass opacity.
    Choe J; Lee SM; Park S; Choi S; Do KH; Seo JB
    Eur Radiol; 2024 Sep; ():. PubMed ID: 39285027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma.
    Murakawa T; Konoeda C; Ito T; Inoue Y; Sano A; Nagayama K; Nakajima J
    Eur J Cardiothorac Surg; 2013 May; 43(5):925-32. PubMed ID: 23047267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic influence of a ground-glass opacity component in hypermetabolic lung adenocarcinoma.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Jan; 61(2):249-256. PubMed ID: 34632486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Ground-Glass Opacities in the Lung Cancer Spectrum.
    Zhang Y; Fu F; Chen H
    Ann Thorac Surg; 2020 Dec; 110(6):1796-1804. PubMed ID: 32525031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the prognostic implication of ground-glass opacity on CT according to pathological nodal status in lung cancers treated with lobectomy or pneumonectomy.
    Park S; Lee SM; Choe J; Choi S; Kim S; Do KH; Seo JB
    Eur Radiol; 2022 Jul; 32(7):4405-4413. PubMed ID: 35141781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions.
    Asamura H; Suzuki K; Watanabe S; Matsuno Y; Maeshima A; Tsuchiya R
    Ann Thorac Surg; 2003 Oct; 76(4):1016-22. PubMed ID: 14529977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions.
    Fu F; Zhang Y; Wen Z; Zheng D; Gao Z; Han H; Deng L; Wang S; Liu Q; Li Y; Shen L; Shen X; Zhao Y; Zhao Z; Ye T; Xiang J; Zhang Y; Sun Y; Hu H; Chen H
    J Thorac Oncol; 2019 Dec; 14(12):2133-2142. PubMed ID: 31437531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Ground-glass Opacity Component on c-Stage IA Lung Adenocarcinoma.
    Li M; Xi J; Sui Q; Kuroda H; Hamanaka K; Bongiolatti S; Hong G; Zhan C; Feng M; Wang Q; Tan L
    Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):783-795. PubMed ID: 35907612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic value of solid component for lung adenocarcinoma shown as ground-glass nodule on computed tomography].
    Ge X; Gao F; Li M; Chen Y; Lü F; Ren Q; Hua Y
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(13):1010-3. PubMed ID: 24851690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers.
    Aoki T; Hanamiya M; Uramoto H; Hisaoka M; Yamashita Y; Korogi Y
    Radiology; 2012 Aug; 264(2):590-6. PubMed ID: 22653188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partly solid pulmonary nodules: waiting for change or surgery outright?
    Seok Y; Cho S; Kim K; Jheon S
    Interact Cardiovasc Thorac Surg; 2014 Oct; 19(4):556-60. PubMed ID: 24981106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct clinicopathologic factors and prognosis based on the presence of ground-glass opacity components in patients with resected stage I non-small cell lung cancer.
    Wang C; Wu Y; Li J; Ren P; Gou Y; Shao J; Zhou Y; Xiao X; Tuersun P; Liu D; Zhang L; Li W
    Ann Transl Med; 2020 Sep; 8(18):1133. PubMed ID: 33240982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.